During the ALV of the OVBSP on 23 June this year, Frank Waardenberg stepped down as treasurer. Frank is succeeded by Jan Schultz, of the company ZoBio
Jan Schultz studied chemical engineering at TU Delft and has been working for contract research organisations in the field of preclinical drug research since the beginning of his professional career.
Jan Schultz joined ZoBio in June 2017 and is currently Managing Director Business Development. ZoBio is a spin-out from Leiden University and the company uses various biophysical techniques to discover and develop potentially new drugs (‘small molecules’). It is a contract research organisation that carries out gene-to-lead research projects for pharmaceutical and biotech companies in Europe, the United States and Japan. ZoBio is located at BioPartner 2 and employs 40 people in the fields of protein production, development of in vitro test systems, structural biology and medicinal chemistry.